To use the Archimedes model to estimate the consequences of delays in oral antidiabetic drug (OAD) treatment intensification on glycaemic control and long-term outcomes at 5 and 20 years.
| INTRODUCTION
The joint American Diabetes Association (ADA)/European Association for the Study of Diabetes position statement recommends that, in case of failure to achieve or sustain glycaemic goals with metformin monotherapy and lifestyle modification, another medication should be added 3 months after the initiation of therapy 1 ; however, among patients with type 2 diabetes who are inadequately responsive to metformin monotherapy, there is often a delay in initiating add-on therapy, known as clinical inertia. 2 Retrospective observational studies have shown that glycaemic control is poor for many patients as a result of clinical inertia, but that the situation could be improved by earlier intensification with oral antidiabetic drug (OAD) therapies. [3] [4] [5] [6] [7] [8] [9] One recent study (the Inertia study) used data from a large US claims database to estimate time to treatment intensification (TTI) with an ‡ Present address Janssen Scientific Affairs, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, United States.
additional OAD or injectable medication for adults with type 2 diabetes and poor glycaemic control (glycated haemoglobin [HbA1c] ≥8%)
after ≥3 months of therapy that included metformin (index date), and no history of injectable antidiabetic medications. 9 The study found that fewer than half of the patients received intensification (48%) within 12 months of the index date.
Despite this existing body of literature on clinical inertia, little is known about its long-term consequences. The objective of the present study was to estimate the potential long-term consequences of clinical inertia. The Archimedes model was used to estimate the consequences of a delay in treatment intensification with a new OAD on glycaemic control and long-term outcomes in patients with uncontrolled type 2 diabetes. The simulated cohort and projections for TTI values were derived from real-world management observed in the Inertia study. 9 
| MATERIALS AND METHODS

| Archimedes model
The Archimedes model, an individual-level simulation of human physiology, patient populations, and healthcare systems, was designed to forecast health outcomes for a variety of diseases, including diabetes and its complications. Details of the Archimedes model and its validations have been described in previous publications. [10] [11] [12] Simulated patients have a profile of demographic and physiological characteristics that reflect the variation observed in the real US population 13 and evolve continuously over time. These characteristics affect a patient's risk of health outcomes such as a myocardial infarction (MI). Care processes in the model are based on current national guidelines, including the ADA guidelines for managing HbA1c. Rates of diagnosis and treatment are calibrated to match national-level statistics to capture the imperfect nature of the real US healthcare system. The model has been validated to 20 trials and cohort studies in a total of 684 validation exercises, 11, 12 and has been used to conduct several studies of diabetes management.
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| Inertia study
The Inertia study was a retrospective cohort study using data from the Truven Health MarketScan Commercial Claims and Encounters, Medicare Supplemental and Coordination of Benefits, and Lab Databases, which include the administrative healthcare claims and encounter records for individuals with private medical insurance coverage, during the period January 2009 to December 31, 2013. 9 The study included patients aged ≥18 years with a diagnosis of type 2 diabetes and receiving metformin therapy. Treatment failure was defined as HbA1c ≥8%. 9 Patients were followed for 1 year after the index date, and the primary outcome was the time from index date to treatment intensification, defined as patients filling a prescription for injectables or additional OADs. Subgroup analyses were based on the number of OADs used at baseline (metformin monotherapy, metformin with 1 other OAD, and metformin with ≥2 other OADs). 9 TTI was categorized into 3 groups: early intensified (within 6 months); late intensified (6-12 months); or not intensified within 12 months. 
| Study population
The simulated cohort was matched to characteristics observed in the Inertia study, 9 including age, sex, HbA1c, estimated glomerular filtration rate (eGFR), anti-hypertensive medication use, and statin use (Table 1) . The simulated population was stratified into 3 cohorts according to the number of OADs used at baseline (ie, patients on 1, 2 or 3 OADs, hereafter referred to as the 1-OAD, 2-OAD and 3-OAD cohorts, respectively). Although the 2-and 3-OAD cohorts were simulated separately, they were combined for the purpose of generating the sample of simulated patients because of limitations of sample size in the National Health and Nutrition Examination Survey (NHANES).
| Delay groups and TTI
The model compared two groups: "delay" and "no delay." In the nodelay group, patients received treatment intensifications at the time intervals recommended by ADA guidelines. 1 The delay group results were a weighted average of the simulations for 3 subgroups stratified by TTI: 0 to 6 months; 6 to 12 months; and >12 months (Table 1) , based on the observed intensification times in the Inertia study. 9 Patients in the 1-OAD cohort intensified substantially faster than patients in the 2-or 3-OAD cohorts; however, the 2-or 3-OAD cohorts intensified at rates similar to each other, and so these were combined for the purpose of fitting and extrapolating the TTI curve.
Further details can be found in File S1 (Section A. Derivation of Time to Intensification).
| Treatment protocol
Patients with an HbA1c value >7% were eligible for treatment intensification with another OAD. 1 All patients were assumed to follow the same treatment sequence, starting with metformin, followed by adding a drug from the sulphonylurea (SU) class, then one of the dipeptidyl peptidase-4 (DPP-4) inhibitors, and finally a thiazolidinedione (TZD). This sequence was based on the most prevalent treatments observed in the Inertia study. 9 Patients were assumed to intensify with an add-on OAD at an average dose. Once patients were on all 4 OADs, they were no longer eligible for further intensification. Other antidiabetic treatments, including insulin, were withheld in the model.
Patients in the 1-, 2-, and 3-OAD cohorts were assumed to be on metformin monotherapy; metformin plus SU dual therapy; and metformin, SU and DPP-4 inhibitor triple therapy, respectively. 
| Treatment efficacy
In the model, metformin reduces fasting plasma glucose, weight, total cholesterol, triglycerides and systolic blood pressure, and increases HDL cholesterol. Adding SU reduces HbA1c but increases weight.
Adding DPP-4 inhibitor to metformin and SU reduces HbA1c only.
Adding TZD to triple therapy decreases fasting plasma glucose and triglycerides and increases weight, total cholesterol and HDL cholesterol. Further details on treatment effects can be found in File S1
(Section B, Treatment Effects).
| Model outcomes
The model included the following macrovascular complications: myocardial infarction (MI), stroke, and heart failure (HF). The primary outcome of interest was major adverse cardiac events (MACE), defined as MI, stroke or death from coronary heart disease. The microvascular complications included neuropathy (leading to foot ulcers and amputations, including toe, foot and ankle, below-knee and above-knee were also included for MI, stroke, foot ulcers and amputation. Mortality included both background mortality and disease-specific mortality.
The only treatment-related adverse event included was medically severe hypoglycaemia, defined as a hypoglycaemia event requiring the assistance of a medical professional. Patients could experience multiple episodes of hypoglycaemia over the time horizon. Hypoglycaemia events were assumed to have no impact on mortality or medication use.
Further details on complications, mortality and hypoglycaemia can be found in File S1 (Section C. Complications of Diabetes and Section D. Hypoglycaemia).
| Base case and scenario analyses
For each of the 12 subgroups (3 OADs and 4 delay strata), 50 000 individual patients were simulated for a total of 600 000 simulated patients. The 3-OAD strata were pooled to compute a value for each of the no-delay subgroups and the 3 delay subgroups, weighted by the observed distribution from the Inertia study (Table 1) . 9 The delay subgroups were then pooled to compute the final value for the delay group. Finally, the no-delay and delay values were compared to compute a relative risk reduction (RRR) for each of the outcomes in the model (or an absolute difference for mean HbA1c). The weights used for computing the pooled estimates are given in Table 1 .
To test outcomes under alternative assumptions of less aggressive treatment, 2 scenario analyses were run. The first assessed the impact of delays in intensification using a glycaemic treatment threshold of 8%. The second used the TTI values from the Weibull projection (Alternative Scenario; Table 1 ), which projected patients in the >12-month group to intensify much earlier than the gamma projection.
| Ethics
This modelling study used only de-identified data, and did not deal with any actual persons or any animals. As a result, no review committee approval for the protocol was required for this work.
| RESULTS
| Population baseline characteristics
The baseline characteristics are given in 
| HbA1c
At 1 year, the absolute reduction in HbA1c values in the no-delay group relative to the delay group was 1.4% percentage points (mean HbA1c 6.8% vs 8.2%). In the 8% goal scenario, the mean difference in HbA1c was only 0.7% (no delay: mean HbA1c 7.7% vs delay:
8.5%). In the alternate TTI scenario, the 1-year HbA1c values were the same as in the base case because this scenario focuses on the long-term pattern of intensification.
| Incidence of MACE
The Kaplan-Meier incidence values of MACE at 5 and 20 years for the delay and no-delay groups and the RRR, stratified by baseline number of OADs, are provided in the upper section of Table 2 .
Across OAD cohorts, the greatest RRR was in the 2-OAD cohort, at both 5 and 20 years. The Kaplan-Meier incidence of MACE over time is shown in Figure 2 , stratified by the number of OADs at baseline and delay subgroup. The risk of MACE was substantially higher for patients delaying intensification by >12 months, and the absolute difference increases over time.
The RRR of MACE for the base case and scenario analyses are provided in the middle section of Table 2 . In the 8% goal scenario, the RRR was smaller than in the base case (from −18.0% to −13.2% at 5 years, and from −9.0% to −7.6% at 20 years), indicating that there is less benefit to timely intensification when the treatment goal is less aggressive. Compared with the base case, the alternate TTI scenario (using the Weibull projection) has a smaller RRR, indicating less benefit of earlier intensification (−17.2% at 5 years, and −5.5% at 20 years). This was to be expected, because the Weibull projection has shorter times to intensification for the >12-month group.
| Other complications
The incidence of each complication at 5 and 20 years for the no-delay and delay groups, as well as the RRR, are provided in the lower section of Table 2 . Among the macrovascular complications, the largest RRR was seen for MI, followed by HF, and then stroke. Among microvascular complications, the largest RRR was seen in amputation. There was a moderate effect on macroalbuminuria, and the effects on blindness and ESRD were relatively small. In general, the RRR values were higher at 5 years than at 20 years, although the absolute differences were greater at 20 years.
In the scenario analyses, the RRR values were somewhat smaller than in the base case, although the ranking between complications did not change. In general, the values in the alternate TTI scenario were similar to the base case, whereas there was a greater difference in the 8% goal scenario. Detailed results of the scenario analyses for each complication are included in File S1 (Section E. Extended Scenario Analysis Results).
| Hypoglycaemia
The incidence of hypoglycaemia at 5 and 20 years is provided in Table 3 . At 5 years, the incidence of hypoglycaemia was 51.7%
higher in the no-delay groups vs the delay group, and at 20 years it was 18.0% higher. In the scenario analyses, the incidence of hypoglycaemia was lower than in the base case because of less aggressive treatment intensification.
| DISCUSSION
The no-delay cohort of patients in whom OAD therapy was intensified according to ADA guidelines achieved a mean HbA1c below the target recommended at 1 year, whereas the delay cohort remained above target at mean HbA1c of 8.2%, a value similar to the observed value of 8.1% in the Inertia study. 9 The assumption of our model that early intensification in accordance with guidelines can improve glycaemic control is consistent with the findings of other retrospective observational studies. For example, a large US retrospective claims study showed that the majority (70%)
of patients who adhered to ADA guidelines achieved the HbA1c target, compared with only 31% of patients who did not. 18 A retrospective analysis of the electronic medical records of patients who failed metformin monotherapy showed that patients receiving early intensification were more likely to attain target HbA1c levels than those who experienced a delay. 8 The model predicts that the differences in HbA1c between patients delaying and not delaying have important long-term consequences for the risk of complications of diabetes. Patients who did not delay intensification experienced a substantial reduction in the risk of MACE, MI, HF and amputation at 5 years, with similar results at 20 years. There was a moderate reduction in the risk of macroalbuminuria, as well as modest reductions in the risk of stroke, blindness and ESRD. HbA1c has been found to be a less important risk factor for stroke 19 and ESRD. 20 Conversely, HbA1c has been found to be an important risk factor for progression of diabetic retinopathy, suggesting the model may have underestimated the effect on blindness. 21 The model also predicted an increase in severe hypoglycaemia for patients in the no-delay cohort.
Two scenario analyses were performed to test the robustness of the model. When the HbA1c treatment target was changed to 8%, the RRR for MACE and other complications was reduced, indicating less benefit when a less aggressive HbA1c goal was used, compared with the base case. The RRR values were also reduced when an alternative assumption was used regarding the extrapolation of the TTI curve after 12 months. A comparison of the extrapolations derived from the Inertia study with a study by Khunti et al. 7 that reported the observed TTI values over longer time periods suggests that the extrapolation used in the base case is relatively conservative, and that, after 12 months, observed rates of intensification are likely to be low. Khunti et al. 7 studied patients in the UK for the time period 2004 to 2011 with an HbA1c ≥8%, and reported median times to intensification of 1.6 and 6.9 years for patients on 1 or 2 OADs.
There is relatively little real-world evidence of the effect of timely intensification on long-term outcomes. The largest study is a retrospective cohort study by Paul et al. 22 of 105 477 patients in the UK, with a mean follow-up time of 5.3 years, in which the authors observed a significant increase in risk of MI, stroke and HF associated with a 12-month delay in intensification for patients with HbA1c >7%. This is in contrast to an earlier cohort study by Neugebauer et al. 23 of 58 000 patients in the USA over 4 years of follow up, in which the authors did not find a significant The economic consequences of tight glycaemic control as compared with current practice in the UK were modelled by Baxter et al. 24 As in the present study, they predicted a large economic impact from preventing foot ulcers and amputation; however, they found little benefit to cardiovascular disease prevention, a discrepancy with the present study. This A network meta-analysis of >300 clinical trials found no association of any glucose-lowering medication with cardiovascular mortality, MI or stroke. 27 Furthermore, some studies suggest DPP-4 inhibitors increase the risk of hospitalization for HF, 28 while others found no association. 29, 30 More recently, a cardiovascular mortality reduction has been demonstrated in a randomized controlled trial for a sodium-glucose cotransporter 2 (SGLT-2) inhibitor 31 ; however, treatment patterns in this study are based on observational data from the Inertia study, which was conducted before the approval of this drug class. Ultimately, these are questions that cannot be resolved by modelling, but must await the completion of further trials and observational studies.
The Archimedes model is a rigorously validated model, [10] [11] [12] 
